Business Context and Reporting Period
Company: Omeros Corporation (OMEROS CORP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on inflammation and central nervous system disorders. The company is classified as a "Development Stage Company" with no products approved for commercial sale. Its primary revenue source is grant funding from government and private institutions. Key product candidates include OMS103HP (PharmacoSurgery platform for ACL reconstruction), OMS302 (ophthalmology), and OMS201 (urology).
Key Financial Metrics (Six Months Ended June 30, 2010)
| Metric | Amount (in thousands) |
|---|---|
| Grant Revenue | $875 |
| Net Loss | $(14,465) |
| Net Loss Per Share (Basic & Diluted) | $(0.68) |
| Research & Development Expenses | $11,202 |
| General & Administrative Expenses | $3,732 |
| Cash and Cash Equivalents | $2,873 |
| Short-term Investments | $39,010 |
| Total Liquidity (Cash + Investments) | $41,883 |
| Total Notes Payable | $10,143 |
| Accumulated Deficit | $(132,801) |
Material Changes vs. Prior Period
- Revenue: Increased to $875,000 for the six months ended June 30, 2010, compared to $568,000 in the same period in 2009. The increase was driven by additional revenue recognition from National Institutes of Health (NIH) grants, partially offset by a decrease in revenue from The Michael J. Fox Foundation.
- Net Loss: Widened to $14.5 million from $11.6 million in the prior year period, primarily due to increased operating expenses.
- Operating Expenses:
- R&D: Increased to $11.2 million from $8.6 million. Drivers included higher contract service costs, accruals for employee bonuses, a one-time $500,000 payment to Helion Biotech for an exclusive license, and a $500,000 payment to Affitech AS to release the company from future royalty obligations.
- G&A: Increased to $3.7 million from $2.9 million, attributed to higher costs associated with being a public company and employee bonus accruals.
- Liquidity: Cash and cash equivalents increased from $820,000 at year-end 2009 to $2,873,000, while short-term investments decreased from $59.5 million to $39.0 million. The company sold mortgage-backed securities in May 2010 and reinvested proceeds in cash equivalents.
Guidance, Outlook, and Risks
- Outlook: Management expects net losses to increase in 2010 as clinical trials advance and personnel/facilities expand. The company anticipates no product revenue until at least 2012. Management believes existing cash and investments are sufficient to fund operations for at least the next 12 months.
- Capital Resources: In July 2010 (subsequent to period end), the company entered into an equity line financing facility with Azimuth Opportunity, Ltd., allowing the sale of up to $40.0 million of common stock over 24 months.
- Key Risks:
- Regulatory Approval: Success depends heavily on the Phase 3 clinical program for OMS103HP. The FDA has questioned study designs and the contribution of active ingredients in combination drugs.
- Litigation: The former CFO, Richard J. Klein, has filed a lawsuit alleging violations of the Federal False Claims Act and wrongful termination. The company is vigorously defending the claims.
- Debt Covenants: The company has a $10.1 million debt facility with BlueCrest Venture Finance. The agreement contains covenants and a "material adverse effect" clause that could trigger immediate repayment if business conditions deteriorate.
- Capital Needs: The company may need to raise additional capital to complete development programs. Failure to do so could force delays or the relinquishment of rights to product candidates.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $41.9 million liquidity position against the projected burn rate for the next 12 months, considering the upcoming Phase 3 trial costs for OMS103HP.
- Debt Obligations: Review the terms of the BlueCrest loan agreement, specifically the "material adverse effect" clause and the 12.5% interest rate, to assess refinancing risk.
- Clinical Milestones: Monitor the timeline and results of the Phase 3 clinical program for OMS103HP in ACL reconstruction surgery, expected to be released by year-end 2010.
- Litigation Status: Track the progress of the lawsuit filed by former CFO Richard J. Klein and any potential financial exposure or reputational damage.
- Grant Dependency: Assess the sustainability of revenue streams, which are currently derived entirely from grants (NIH, SMRI, MJFF) rather than product sales.